Compare Incyte Corporation (INCY) vs Roundhill Magnificent Seven ETF (MAGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Roundhill Magnificent Seven ETF — how do they compare? Incyte Corporation trades at $112.79 (market cap $22.85B), while Roundhill Magnificent Seven ETF trades at $73.73 (market cap $5.78B). The key difference: Incyte Corporation is far larger — about 4× Roundhill Magnificent Seven ETF's market cap, and Roundhill Magnificent Seven ETF is trading nearer its 52-week high, Incyte Corporation nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and Roundhill Magnificent Seven ETF for 36 Days on average.
| INCY | MAGS | |
|---|---|---|
Market Cap | $22.85B | $5.78B |
Volume | 1,927,029 | 4,410,665 |
Sector | Health | Sector/Thematic |
52-Week High | $129.93 | $73.90 |
52-Week Low | $83.80 | $55.39 |
Typical Hold Time | 33 Days | 36 Days |
Enterprise Value | $18.35B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $112.75, down 0.61% today, with a bearish technical signal but strong fundamentals. The stock shows robust profitability with a 27.71% net income margin and 30.67% ROE. Recent news includes FDA approval for Atebrioz and expansion of its inflammation portfolio, supporting growth beyond its key drug JAKAFI. Revenue grew to $5.14 billion in 2025, with net income surging to $1.29 billion, reflecting improved operational efficiency.
The outlook is positive with a consensus price target of $132.43, implying 17% upside, though near-term earnings pressure and JAKAFI's patent expiry after 2029 pose risks. Analyst sentiment is bullish (52% buy ratings), but technical indicators suggest caution with key support at $111. Execution on pipeline diversification remains critical for sustained growth.
MAGS (Roundhill Magnificent Seven ETF) trades at $73.03, down 0.9% on the day but maintains a bullish technical outlook with strong moving average signals. The ETF provides equal-weighted exposure to seven mega-cap tech leaders, though it has underperformed the broader market in 2026 with only 2% year-to-date gains. Recent news highlights the ongoing debate about the Magnificent Seven's leadership role as AI spending shifts focus toward semiconductor companies.
The ETF faces near-term pressure from reduced tech dividends and buybacks, but long-term AI exposure remains compelling. Key risks include concentration in seven stocks and market rotation away from mega-caps. Technical support at $71-72 provides a cushion, while resistance at $74-75 represents the next challenge for bullish momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Roundhill Magnificent Seven ETF
MAGS is an ETF that provides concentrated exposure to the seven technology-focused mega-cap companies often referred to as the 'Magnificent Seven' (Alphabet, Amazon, Apple, Meta, Microsoft, NVIDIA, and Tesla). The fund is designed to capture the performance of these market-leading stocks, which have been the primary drivers of market returns. It offers a simple way for investors to invest solely in this select group of high-growth technology companies.
Read more on MAGS →
